The Depression in Alzheimer’s Disease Study-2 was a randomized,
placebo-controlled, multi-center trial designed to evaluate the efficacy and safety of sertraline for the treatment of
depression in patients with Alzheimer’s disease. Sertraline was tested in parallel at a target dose of
100 mg b.i.d. (range 25-125 mg b.i.d.) against a matched placebo. The trial enrolled 131 participants who meet
criteria for depression of Alzheimer’s disease. Participants were evaluated with structured, standardized
methods of diagnosis and assessment.
DIADS-2 datasets are available upon request. All requests must be vetted by the DIADS-2 Steering Committee and must
include a detailed analysis proposal and proof of IRB approval for the proposed project. Requests can be submitted to
the address provided in the Contacts page of this website.